Notícias

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.

Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

These high-yield stocks have long track records of dividend consistency and growth.

Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart disease segment. The setback directly affects the competitive position of Pfizer, which markets its own ATTR-CM therapy. Investors are assessing how this development could influence future adoption patterns and revenue potential in ATTR-CM. Pfizer, traded as NYSE:PFE, enters this news cycle with its stock at $24.25 and a value score of 4, alongside mixed multi-year...

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.7% a

It’s the right time to jump in on dividend stocks. Clorox, Pfizer, Verizon and Comcast are some of the names to consider.

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Both McDonald's and Pfizer are blue-chip laggards trading at a discount, both cut reliable dividend checks, and both promise retirees a place to park serious money. But one of them carries hidden risks that could quietly wreck an income portfolio.

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

Pfizer Inc. (NYSE:PFE) was among the stocks Jim Cramer shared his opinions on during Mad Money. A caller asked for Cramer’s thoughts regarding the stock, and he replied: Okay, they do have earnings growth problems. They haven’t been able to make the Seagen acquisition work the way it should. The dividend is safe at 7%. […]

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.

Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' ai

AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.

The U.S. Food and Drug Administration recently expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This label expansion enhances the commercial and clinical importance of IBRANCE within Pfizer’s oncology franchise at a time when the company faces pressure from upcoming patent expirations and weaker COVID-related revenues. We’ll now examine how this new maintenance indication for...

Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC’s Mad Money, a caller from Orland Park, Illinois pitched Pfizer as an income-and-value setup, and Cramer conceded the case looked tempting. He landed on a ... ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

AstraZeneca and Ionis Pharmaceuticals shares are down roughly 8% and 20%, respectively, after the drugmakers said their heart therapy Wainua failed in a late-stage trial. The companies pointed to a smaller group of patients in the trial to show some potential for the drug: Patients who weren’t already taking either Pfizer or BridgeBio’s drug for this condition saw a relative risk reduction in major heart problems or deaths.

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears. The ... 3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri